Your browser doesn't support javascript.
loading
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing.
Achar, Jay; Seddon, James A; Knight, Gwenan M; Dodd, Peter J; Esmail, Hanif; Hughes, Jennifer; McQuaid, C Finn.
  • Achar J; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden jay.achar@ki.se.
  • Seddon JA; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Knight GM; Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK.
  • Dodd PJ; TB Modelling Group, TB Centre, Centre for Mathematical Modelling of Infectious Diseases and AMR Centre, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Esmail H; School of Health and Related Research, University of Sheffield, Sheffield, UK.
  • Hughes J; MRC Clinical Trials Unit, University College London, London, UK.
  • McQuaid CF; Institute for Global Health, University College London, London, UK.
Eur Respir J ; 62(5)2023 11.
Article en En | MEDLINE | ID: mdl-37945035
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis Resistente a Múltiples Medicamentos / Mycobacterium tuberculosis Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis Resistente a Múltiples Medicamentos / Mycobacterium tuberculosis Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article